Cyclacel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CYCC) $0.30 +0.01 (+3.47%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$0.28▼$0.3250-Day Range$0.27▼$0.7552-Week Range$0.27▼$1.17Volume167,024 shsAverage Volume91,310 shsMarket Capitalization$3.77 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cyclacel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,582.8% Upside$8.00 Price TargetShort InterestHealthy4.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.76) to ($3.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Cyclacel Pharmaceuticals has a forecasted upside of 2,582.8% from its current price of $0.30.Amount of Analyst CoverageCyclacel Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.87% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 1.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYCC. Previous Next 2.6 News and Social Media Coverage News SentimentCyclacel Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest5 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.47% of the stock of Cyclacel Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.33% of the stock of Cyclacel Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to decrease in the coming year, from ($1.76) to ($3.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More CYCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCC Stock News HeadlinesNovember 28, 2023 | benzinga.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 28, 2023 | finance.yahoo.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 27, 2023 | msn.comCyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94November 24, 2023 | morningstar.comCyclacel Pharmaceuticals Inc CYCCNovember 24, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)October 19, 2023 | msn.comCyclacel Pharmaceuticals, Inc. PFD CONV EX 6% goes ex dividend tomorrowAugust 9, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37MNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 9, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsJuly 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's WhyJune 15, 2023 | forbes.comJointown Pharmaceutical GroupMay 26, 2023 | msn.comOppenheimer Maintains Cyclacel Pharmaceuticals (CYCC) Outperform RecommendationMay 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditMarch 8, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | msn.comOppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To KnowMarch 3, 2023 | msn.comA Preview Of Cyclacel Pharmaceuticals's EarningsJanuary 30, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor ConferenceDecember 15, 2022 | finance.yahoo.comCyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023November 9, 2022 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | msn.comEarnings Outlook For Cyclacel PharmaceuticalsNovember 7, 2022 | finance.yahoo.comHere's What to Expect Ahead of Wix's (WIX) Q3 Earnings ReleaseOctober 26, 2022 | finance.yahoo.comCyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022October 14, 2022 | fool.comCyclacel Pharmaceuticals (NASDAQ: CYCC)October 13, 2022 | finance.yahoo.comCyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR SymposiumAugust 11, 2022 | seekingalpha.comCyclacel stock rises 16% as net loss narrows, income growsSee More Headlines Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCC CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees2,018Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+2,582.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,200,000.00 Net MarginsN/A Pretax Margin-7,578.55% Return on Equity-241.30% Return on Assets-112.58% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book0.24Miscellaneous Outstanding Shares12,640,000Free Float11,572,000Market Cap$3.77 million OptionableNot Optionable Beta1.06 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 64)President, CEO & Executive Director Comp: $763.55kMr. Paul McBarron (Age 62)Executive VP of Finance, CFO, COO, Secretary & Executive Director Comp: $394.68kDr. Mark H. Kirschbaum M.D. (Age 62)Senior VP & Chief Medical Officer Comp: $523.84kMs. Gill Christie (Age 66)Director of Human Resources Key CompetitorsLucy Scientific DiscoveryNASDAQ:LSDIRedHill BiopharmaNASDAQ:RDHLUniverse PharmaceuticalsNYSE:UPCAyala PharmaceuticalsNASDAQ:ADXSFirst Wave BioPharmaNASDAQ:FWBIView All Competitors CYCC Stock Analysis - Frequently Asked Questions Should I buy or sell Cyclacel Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks. What is Cyclacel Pharmaceuticals' stock price target for 2024? 1 analysts have issued 12-month price objectives for Cyclacel Pharmaceuticals' stock. Their CYCC share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 2,582.8% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts. How have CYCC shares performed in 2023? Cyclacel Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, CYCC stock has decreased by 55.3% and is now trading at $0.2982. View the best growth stocks for 2023 here. When is Cyclacel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our CYCC earnings forecast. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.12. When did Cyclacel Pharmaceuticals' stock split? Cyclacel Pharmaceuticals shares reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO? 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA). How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CYCC) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.